

Annalisa Perna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6824990/publications.pdf>

Version: 2024-02-01

108
papers

13,113
citations

38742

50
h-index

27406

106
g-index

109
all docs

109
docs citations

109
times ranked

10167
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. <i>Lancet, The</i> , 1997, 349, 1857-1863.	13.7	1,725
2	Preventing Microalbuminuria in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2004, 351, 1941-1951.	27.0	952
3	Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. <i>Lancet, The</i> , 1999, 354, 359-364.	13.7	800
4	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. <i>Kidney International</i> , 2011, 79, 1331-1340.	5.2	609
5	Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. <i>Lancet, The</i> , 2005, 365, 939-946.	13.7	594
6	Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. <i>Lancet, The</i> , 1998, 352, 1252-1256.	13.7	522
7	Long-Term Outcome of Renal Transplantation from Older Donors. <i>New England Journal of Medicine</i> , 2006, 354, 343-352.	27.0	453
8	Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. <i>Kidney International</i> , 1998, 53, 1209-1216.	5.2	378
9	Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy. <i>New England Journal of Medicine</i> , 1993, 329, 85-89.	27.0	370
10	Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. <i>The Lancet Global Health</i> , 2016, 4, e307-e319.	6.3	350
11	Sodium Intake, ACE Inhibition, and Progression to ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 165-173.	6.1	275
12	Rituximab in Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1416-1425.	6.1	252
13	Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. <i>Kidney International</i> , 2003, 63, 2254-2261.	5.2	244
14	Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. <i>BMJ: British Medical Journal</i> , 1998, 316, 504-509.	2.3	221
15	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2013, 382, 1485-1495.	13.7	218
16	Rituximab in Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1851-1857.	6.1	208
17	Role of Remission Clinics in the Longitudinal Treatment of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1213-1224.	6.1	192
18	Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE Inhibition. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1923-1930.	6.1	190

#	ARTICLE	IF	CITATIONS
19	ACE Inhibitors to Prevent End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2001, 12, 2832-2837.	6.1	185
20	Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases, 2000, 35, 1155-1165.	1.9	174
21	B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2016, 27, 1811-1822.	6.1	174
22	Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney International, 2003, 63, 1094-1103.	5.2	167
23	Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet, The, 2016, 388, 2629-2641.	13.7	167
24	In Chronic Nephropathies Prolonged ACE Inhibition Can Induce Remission. Journal of the American Society of Nephrology: JASN, 1999, 10, 997-1006.	6.1	161
25	Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver International, 2006, 26, 1040-1046.	3.9	136
26	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes, 2018, 67, 1414-1427.	0.6	136
27	Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood, 2014, 123, 822-828.	1.4	130
28	Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 2729-2737.	6.1	125
29	ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria. Journal of the American Society of Nephrology: JASN, 2011, 22, 1122-1128.	6.1	119
30	Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results. Journal of the American Society of Nephrology: JASN, 2004, 15, 3117-3125.	6.1	112
31	Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet, The, 2002, 359, 663-666.	13.7	110
32	Natural History and Outcome of Hepatic Vascular Malformations in a Large Cohort of Patients with Hereditary Hemorrhagic Teleangiectasia. Digestive Diseases and Sciences, 2011, 56, 2166-2178.	2.3	106
33	Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood, 2012, 119, 3269-3275.	1.4	106
34	Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. American Journal of Kidney Diseases, 2004, 44, 385-401.	1.9	97
35	Chronic Proteinuric Nephropathies. II. Outcomes and Response to Treatment in a Prospective Cohort of 352 Patients. Journal of the American Society of Nephrology: JASN, 2000, 11, 88-96.	6.1	91
36	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2018, 29, 283-294.	6.1	89

#	ARTICLE	IF	CITATIONS
37	Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus. Hypertension, 2011, 58, 776-783.	2.7	86
38	Rituximab for Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 738-748.	4.5	83
39	Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 1717-1724.	6.1	80
40	ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. Kidney International, 2000, 57, 274-281.	5.2	75
41	An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2019, 74, 56-72.	1.9	71
42	Sirt3 Deficiency Shortens Life Span and Impairs Cardiac Mitochondrial Function Rescued by Opa1 Gene Transfer. Antioxidants and Redox Signaling, 2019, 31, 1255-1271.	5.4	70
43	Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the BENEDICT Trial. Journal of the American Society of Nephrology: JASN, 2006, 17, 3472-3481.	6.1	67
44	Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial. Diabetes, 2017, 66, 75-86.	0.6	66
45	Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies. Circulation, 2003, 107, 586-592.	1.6	65
46	Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of Hypertension, 2011, 29, 207-216.	0.5	62
47	Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. American Journal of Kidney Diseases, 2004, 44, 385-401.	1.9	56
48	Immunosuppression for Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 787-796.	4.5	54
49	SEQUENTIAL MONITORING OF URINE-SOLUBLE INTERLEUKIN 2 RECEPTOR AND INTERLEUKIN 6 PREDICTS ACUTE REJECTION OF HUMAN RENAL ALLOGRAFTS BEFORE CLINICAL OR LABORATORY SIGNS OF RENAL DYSFUNCTION. Transplantation, 1997, 63, 1508-1514.	1.0	53
50	Abnormal permeability to proteins and glomerular lesions: A meta-analysis of experimental and human studies. American Journal of Kidney Diseases, 1996, 27, 34-41.	1.9	51
51	Paricalcitol for Secondary Hyperparathyroidism in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2015, 26, 1205-1214.	6.1	51
52	Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. The Cochrane Library, 2014, , CD004293.	2.8	50
53	Plasma Exchange in Children With Hemolytic-Uremic Syndrome at Risk of Poor Outcome. American Journal of Kidney Diseases, 1993, 22, 264-266.	1.9	48
54	Long-term outcome of renal transplantation from octogenarian donors: A multicenter controlled study. American Journal of Transplantation, 2017, 17, 3159-3171.	4.7	47

#	ARTICLE	IF	CITATIONS
55	Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1022-1030.e4.	4.4	45
56	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 224-238.	1.9	45
57	Basiliximab Combined with Low-Dose Rabbit Anti-Human Thymocyte Globulin: A Possible Further Step toward Effective and Minimally Toxic T Cell Targeted Therapy in Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 546-554.	4.5	44
58	Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. <i>American Journal of Kidney Diseases</i> , 2004, 44, 385-401.	1.9	44
59	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. <i>PLoS Medicine</i> , 2019, 16, e1002777.	8.4	42
60	Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. <i>The Cochrane Library</i> , 2008, , CD003233.	2.8	38
61	Effects of Add-on Fluvastatin Therapy in Patients with Chronic Proteinuric Nephropathy on Dual Renin-Angiotensin System Blockade. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1928-1938.	4.5	37
62	Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 19-27.	11.4	37
63	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 785-794.	4.5	35
64	The Bergamo Nephrologic Diabetes Complications Trial (BENEDICT): design and baseline characteristics. <i>Contemporary Clinical Trials</i> , 2003, 24, 442-461.	1.9	34
65	Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1629-1634.	8.6	33
66	Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. <i>BMJ Open</i> , 2012, 2, bmjopen-2012-001357.	1.9	32
67	Community-Based Screening for Chronic Kidney Disease, Hypertension and Diabetes in Dharan. <i>Journal of the Nepal Medical Association</i> , 2013, 52, 205-212.	0.4	32
68	Outcome of Renal Transplantation from Very Old Donors. <i>New England Journal of Medicine</i> , 2009, 360, 1464-1465.	27.0	29
69	Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. , 2004, , CD004293.		28
70	Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? A systematic review. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2005, 6, 16.	1.5	28
71	Renal Transplantation: Can We Reduce Calcineurin Inhibitor/Stop Steroids? Evidence Based on Protocol Biopsy Findings. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 755-766.	6.1	27
72	Blood Pressure and Metabolic Effects of Acetyl-L-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial. <i>Journal of the Endocrine Society</i> , 2018, 2, 420-436.	0.2	25

#	ARTICLE	IF	CITATIONS
73	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0261113.	2.5	25
74	Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM). <i>Systematic Reviews</i> , 2014, 3, 69.	5.3	24
75	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 27-40.	11.4	24
76	Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 475-476.	0.9	23
77	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. <i>Kidney International</i> , 1992, 42, 981-990.	5.2	21
78	Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience. <i>Nephron</i> , 2018, 140, 1-8.	1.8	21
79	More Concern About Transfusion Requirement When Evaluating Quality of Life in Anemic Patients. <i>Journal of Clinical Oncology</i> , 2002, 20, 3182-3184.	1.6	19
80	Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 695-703.	1.5	19
81	Nonimmunosuppressive therapy of membranous nephropathy. <i>Seminars in Nephrology</i> , 2003, 23, 333-339.	1.6	18
82	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 338-350.	1.9	17
83	Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial. <i>Journal of Ophthalmology</i> , 2010, 2010, 1-9.	1.3	16
84	The Remission Clinic approach to halt the progression of kidney disease. <i>Journal of Nephrology</i> , 2011, 24, 274-281.	2.0	16
85	Single strand conformation polymorphism (SSCP) as a quick and reliable method to genotype M235T polymorphism of angiotensinogen gene. <i>Clinical Biochemistry</i> , 2002, 35, 363-368.	1.9	14
86	Mycophenolate Mofetil Versus Azathioprine in Organ Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, 2856-2857.	4.7	14
87	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1177-1190.	4.4	14
88	Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. <i>Frontiers in Genetics</i> , 2019, 10, 681.	2.3	11
89	Pretreatment blood pressure reliably predicts progression of chronic nephropathies. <i>Kidney International</i> , 2000, 58, 2093-2101.	5.2	10
90	Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. <i>Kidney International</i> , 2003, 63, 1924-1933.	5.2	10

#	ARTICLE	IF	CITATIONS
91	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 291-303.	6.1	10
92	Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial). <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109804.	2.8	10
93	Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. <i>Journal of Transplantation</i> , 2012, 2012, 1-7.	0.5	9
94	A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study. <i>Nephron</i> , 2015, 130, 13-20.	1.8	9
95	Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial. <i>PLoS Medicine</i> , 2021, 18, e1003668.	8.4	8
96	Recent developments in the management of membranous nephropathy. <i>Expert Opinion on Investigational Drugs</i> , 1997, 6, 521-532.	4.1	7
97	Preventing microalbuminuria with benazepril, valsartan, and benazepril+valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. <i>PLoS Medicine</i> , 2021, 18, e1003691.	8.4	7
98	Chronic Nephropathies: Individual Risk for Progression to End-Stage Renal Failure as Predicted by an Integrated Probabilistic Model. <i>Nephron Clinical Practice</i> , 2003, 95, c47-c59.	2.3	6
99	Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 575-587.	4.5	6
100	Preventing Microalbuminuria in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2005, 352, 833-834.	27.0	5
101	Preimplantation Histological Score Associates with 6-Month GFR in Recipients of Perfused, Older Kidney Grafts: Results from a Pilot Study. <i>Nephron</i> , 2021, 145, 137-149.	1.8	3
102	Non-diabetic nephropathies and ACE inhibition. <i>Lancet</i> , The, 1999, 354, 1905-1906.	13.7	2
103	Quality of life in myelofibrosis with myeloid metaplasia: a cross-sectional study. <i>Leukemia Research</i> , 2003, 27, 763-764.	0.8	2
104	Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. <i>Acta Diabetologica</i> , 2022, 59, 309-317.	2.5	2
105	Low-Molecular-Weight Heparin and Recurrent Placenta-Mediated Pregnancy Complications: A Meta-analysis of Individual Patient Data From Randomised Controlled Trials. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 153-155.	0.4	1
106	Effect of intensive blood pressure on the progression of non-diabetic chronic kidney disease at varying degrees of proteinuria. <i>Journal of Investigative Medicine</i> , 2021, 69, 1035-1043.	1.6	1
107	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 95-105.	0.2	1
108	Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial. <i>Diabetes Care</i> , 2010, 33, e133-e133.	8.6	0